

USSN 09/554,533  
Atty Docket No. 238/086US

### AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application:

#### Listing of Claims:

1. (Withdrawn) A peptide compound of the formula (I) [SEQ. ID. NO. 4]:

Xaa<sub>1</sub> Xaa<sub>2</sub> Xaa<sub>3</sub> Gly Xaa<sub>5</sub> Xaa<sub>6</sub> Xaa<sub>7</sub> Xaa<sub>8</sub> Xaa<sub>9</sub> Xaa<sub>10</sub>  
Xaa<sub>11</sub> Xaa<sub>12</sub> Xaa<sub>13</sub> Xaa<sub>14</sub> Xaa<sub>15</sub> Xaa<sub>16</sub> Xaa<sub>17</sub> Ala Xaa<sub>19</sub> Xaa<sub>20</sub>  
Xaa<sub>21</sub> Xaa<sub>22</sub> Xaa<sub>23</sub> Xaa<sub>24</sub> Xaa<sub>25</sub> Xaa<sub>26</sub> Xaa<sub>27</sub> Xaa<sub>28</sub>-Z<sub>1</sub>; wherein

Xaa<sub>1</sub> is His, Arg or Tyr;  
Xaa<sub>2</sub> is Ser, Gly, Ala or Thr;  
Xaa<sub>3</sub> is Asp or Glu;  
Xaa<sub>5</sub> is Ala or Thr;  
Xaa<sub>6</sub> is Ala, Phe, Tyr or naphthylalanine;  
Xaa<sub>7</sub> is Thr or Ser;  
Xaa<sub>8</sub> is Ala, Ser or Thr;  
Xaa<sub>9</sub> is Asp or Glu;  
Xaa<sub>10</sub> is Ala, Leu, Ile, Val, pentylglycine or Met;  
Xaa<sub>11</sub> is Ala or Ser;  
Xaa<sub>12</sub> is Ala or Lys;  
Xaa<sub>13</sub> is Ala or Gln;  
Xaa<sub>14</sub> is Ala, Leu, Ile, pentylglycine, Val or Met;  
Xaa<sub>15</sub> is Ala or Glu;  
Xaa<sub>16</sub> is Ala or Glu;  
Xaa<sub>17</sub> is Ala or Glu;  
Xaa<sub>19</sub> is Ala or Val;  
Xaa<sub>20</sub> is Ala or Arg;

USSN 09/554,533  
Atty Docket No. 238/086US

Xaa<sub>21</sub> is Ala or Leu;

Xaa<sub>22</sub> is Phe, Tyr or naphthylalanine;

Xaa<sub>23</sub> is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;

Xaa<sub>24</sub> is Ala, Glu or Asp;

Xaa<sub>25</sub> is Ala, Trp, Phe, Tyr or naphthylalanine;

Xaa<sub>26</sub> is Ala or Leu;

Xaa<sub>27</sub> is Ala or Lys;

Xaa<sub>28</sub> is Ala or Asn;

Z<sub>1</sub> is -OH,

-NH<sub>2</sub>,

Gly-Z<sub>2</sub>,

Gly Gly -Z<sub>2</sub>

Gly Gly Xaa<sub>31</sub>-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub>-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub>-Z<sub>2</sub> or

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub> Xaa<sub>38</sub>-Z<sub>2</sub>;

wherein

Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine and N-alkylalanine; and

Z<sub>2</sub> is -OH or -NH<sub>2</sub>;

provided that no more than three of Xaa<sub>3</sub>, Xaa<sub>5</sub>, Xaa<sub>6</sub>, Xaa<sub>8</sub>, Xaa<sub>10</sub>, Xaa<sub>11</sub>, Xaa<sub>12</sub>, Xaa<sub>13</sub>, Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub>, Xaa<sub>17</sub>, Xaa<sub>19</sub>, Xaa<sub>20</sub>, Xaa<sub>21</sub>, Xaa<sub>24</sub>, Xaa<sub>25</sub>, Xaa<sub>26</sub>, Xaa<sub>27</sub>, and Xaa<sub>28</sub> are Ala; and

USSN 09/554,533  
Atty Docket No. 238/086US

pharmaceutically acceptable salts thereof.

2. (Withdrawn) A compound according to claim 1 wherein Xaa<sub>1</sub> is His or Tyr.
3. (Withdrawn) A compound according to claim 2 wherein Xaa<sub>1</sub> is His.
4. (Withdrawn) A compound according to claim 2 wherein Xaa<sub>2</sub> is Gly.
5. (Withdrawn) A compound according to claim 4 wherein Xaa<sub>14</sub> is Leu, pentylglycine or Met.
6. (Withdrawn) A compound according to claim 5 wherein Xaa<sub>25</sub> is Trp or Phe.
7. (Withdrawn) A compound according to claim 6 wherein Xaa<sub>6</sub> is Phe or naphthylalanine; and Xaa<sub>22</sub> is Phe or naphthylalanine; Xaa<sub>23</sub> is Ile or Val.
8. (Withdrawn) A compound according to claim 7 wherein Z<sub>1</sub> is -NH<sub>2</sub>.
9. (Withdrawn) A compound according to claim 7 wherein Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> are independently selected from the group consisting of Pro, homoproline, thioproline and N-alkylalanine.
10. (Withdrawn) A compound according to claim 9 wherein Z<sub>2</sub> is -NH<sub>2</sub>.
11. (Withdrawn) A compound according to claim 1 wherein Xaa<sub>2</sub> is Gly.
12. (Withdrawn) A compound according to claim 1 wherein Xaa<sub>14</sub> is Leu, pentylglycine or Met.
13. (Withdrawn) A compound according to claim 1 wherein Xaa<sub>25</sub> is Trp or Phe.

USSN 09/554,533  
Atty Docket No. 238/086US

14. (Withdrawn) A compound according to claim 1 wherein Xaa<sub>6</sub> is Phe or naphthylalanine; Xaa<sub>22</sub> is Phe or naphthylalanine; Xaa<sub>23</sub> is Ile or Val.

15. (Withdrawn) A compound according to claim 1 wherein Z<sub>1</sub> is -NH<sub>2</sub>.

16. (Withdrawn) A compound according to claim 1 wherein Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> are independently selected from the group consisting of Pro, homoproline, thioproline and N-alkylalanine.

17. (Withdrawn) A compound according to claim 1 wherein Z<sub>2</sub> is -NH<sub>2</sub>.

18. (Withdrawn) A compound according to claim 1 which has an amino acid sequence selected from SEQ. ID. NOS. 5 to 65.

19. (Withdrawn) A peptide compound of the formula (I) [SEQ. ID. NO. 4]:

Xaa<sub>1</sub> Xaa<sub>2</sub> Xaa<sub>3</sub> Gly Xaa<sub>5</sub> Xaa<sub>6</sub> Xaa<sub>7</sub> Xaa<sub>8</sub> Xaa<sub>9</sub> Xaa<sub>10</sub>  
Xaa<sub>11</sub> Xaa<sub>12</sub> Xaa<sub>13</sub> Xaa<sub>14</sub> Xaa<sub>15</sub> Xaa<sub>16</sub> Xaa<sub>17</sub> Ala Xaa<sub>18</sub> Xaa<sub>19</sub>  
Xaa<sub>20</sub> Xaa<sub>21</sub> Xaa<sub>22</sub> Xaa<sub>23</sub> Xaa<sub>24</sub> Xaa<sub>25</sub> Xaa<sub>26</sub> Xaa<sub>27</sub> Xaa<sub>28</sub>-Z<sub>1</sub>;

wherein

Xaa<sub>1</sub> is His or Arg;

Xaa<sub>2</sub> is Gly or Ala;

Xaa<sub>3</sub> is Asp or Glu;

Xaa<sub>5</sub> is Ala or Thr;

Xaa<sub>6</sub> is Ala, Phe or naphthylalanine;

Xaa<sub>7</sub> is Thr or Ser;

Xaa<sub>8</sub> is Ala, Ser or Thr;

Xaa<sub>9</sub> is Asp or Glu;

USSN 09/554,533  
Atty Docket No. 238/086US

Xaa<sub>10</sub> is Ala, Leu or pentylglycine;

Xaa<sub>11</sub> is Ala or Ser;

Xaa<sub>12</sub> is Ala or Lys;

Xaa<sub>13</sub> is Ala or Gln;

Xaa<sub>14</sub> is Ala, Leu or pentylglycine;

Xaa<sub>15</sub> is Ala or Glu;

Xaa<sub>16</sub> is Ala or Glu;

Xaa<sub>17</sub> is Ala or Glu;

Xaa<sub>19</sub> is Ala or Val;

Xaa<sub>20</sub> is Ala or Arg;

Xaa<sub>21</sub> is Ala or Leu;

Xaa<sub>22</sub> is Phe or naphthylalanine;

Xaa<sub>23</sub> is Ile, Val or tert-butylglycine;

Xaa<sub>24</sub> is Ala, Glu or Asp;

Xaa<sub>25</sub> is Ala, Trp, or Phe;

Xaa<sub>26</sub> is Ala or Leu;

Xaa<sub>27</sub> is Ala or Lys;

Xaa<sub>28</sub> is Ala or Asn;

Z<sub>1</sub> is -OH,

-NH<sub>2</sub>,

Gly-Z<sub>2</sub>,

Gly Gly -Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub>-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub>-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub>-Z<sub>2</sub> or Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub>

Xaa<sub>37</sub> Xaa<sub>38</sub>-Z<sub>2</sub>;

USSN 09/554,533  
Atty Docket No. 238/086US

Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> are independently selected from the group consisting of Pro, homoproline, thioproline and N-methylalanine; and Z<sub>2</sub> is -OH or -NH<sub>2</sub>; provided that no more than three of Xaa<sub>3</sub>, Xaa<sub>5</sub>, Xaa<sub>6</sub>, Xaa<sub>8</sub>, Xaa<sub>10</sub>, Xaa<sub>11</sub>, Xaa<sub>12</sub>, Xaa<sub>13</sub>, Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub>, Xaa<sub>17</sub>, Xaa<sub>19</sub>, Xaa<sub>20</sub>, Xaa<sub>21</sub>, Xaa<sub>24</sub>, Xaa<sub>25</sub>, Xaa<sub>26</sub>, Xaa<sub>27</sub> and Xaa<sub>28</sub> are Ala; and pharmaceutically acceptable salts thereof.

20. (Withdrawn) A compound according to claim 19 which has an amino acid sequence selected from SEQ. ID. NOS. 6-19.

21. (Withdrawn) A composition comprising a compound of any of claims 1 to 19 in a pharmaceutically acceptable carrier.

22. (Withdrawn) A composition comprising a compound of claim 20 in a pharmaceutically acceptable carrier.

23. (Withdrawn) A method for the treatment of diabetes mellitus comprising the administration of a therapeutically effective amount of a compound according to claim 1.

24. (Withdrawn) A method for the treatment of diabetes mellitus comprising the administration of a therapeutically effective amount of a compound according to claim 18.

25. (Withdrawn) A method for the treatment of diabetes mellitus comprising the administration of a therapeutically effective amount of a compound according to claim 19.

26. (Withdrawn) A method for the treatment of diabetes mellitus comprising the administration of a therapeutically effective amount of a compound according to claim 20.

27. (Withdrawn) The method of claim 23 further comprising the administration of a therapeutically effective amount of an insulin.

USSN 09/554,533  
Atty Docket No. 238/086US

28. (Withdrawn) The method of claim 24 further comprising the administration of a therapeutically effective amount of an insulin.

29. (Withdrawn) The method of claim 25 further comprising the administration of a therapeutically effective amount of an insulin.

30. (Withdrawn) The method of claim 26 further comprising the administration of a therapeutically effective amount of an insulin.

31. (Withdrawn) A method for the treatment of a hyperglycemic condition in a mammal comprising the step of administering a therapeutically effective amount of a compound according to claim 1.

32. (Withdrawn) A method for the treatment of a hyperglycemic condition in a mammal comprising the step of administering a therapeutically effective amount of a compound according to claim 18.

33. (Withdrawn) A method for the treatment of a hypoglycemic condition in a mammal comprising the step of administering a therapeutically effective amount of a compound according to claim 19.

34. (Withdrawn) A method for the treatment of a hypoglycemic condition in a mammal comprising the step of administering a therapeutically effective amount of a compound according to claim 20.

35. (Withdrawn) A peptide compound of the formula (II) [SEQ. ID. NO. 66]:

5                    10  
Xaa<sub>1</sub> Xaa<sub>2</sub> Xaa<sub>3</sub> Gly Xaa<sub>5</sub> Xaa<sub>6</sub> Xaa<sub>7</sub> Xaa<sub>8</sub> Xaa<sub>9</sub> Xaa<sub>10</sub>  
Xaa<sub>11</sub> Xaa<sub>12</sub> Xaa<sub>13</sub> Xaa<sub>14</sub> Xaa<sub>15</sub> Xaa<sub>16</sub> Xaa<sub>17</sub> Ala Xaa<sub>19</sub> Xaa<sub>20</sub>

USSN 09/554,533  
Atty Docket No. 238/086US

Xaa<sub>1</sub> Xaa<sub>2</sub> Xaa<sub>3</sub> Xaa<sub>4</sub> Xaa<sub>5</sub> Xaa<sub>6</sub> X<sub>1</sub>-Z<sub>1</sub>; wherein

Xaa<sub>1</sub> is His, Arg or Tyr or 4-imidazopropionyl;

Xaa<sub>2</sub> is Ser, Gly, Ala or Thr;

Xaa<sub>3</sub> is Asp or Glu;

Xaa<sub>5</sub> is Ala or Thr;

Xaa<sub>6</sub> is Ala, Phe, Tyr or naphthylalanine;

Xaa<sub>7</sub> is Thr or Ser;

Xaa<sub>8</sub> is Ala, Ser or Thr;

Xaa<sub>9</sub> is Asp or Glu;

Xaa<sub>10</sub> is Ala, Leu, Ile, Val, pentylglycine or Met;

Xaa<sub>11</sub> is Ala or Ser;

Xaa<sub>12</sub> is Ala or Lys;

Xaa<sub>13</sub> is Ala or Gln;

Xaa<sub>14</sub> is Ala, Leu, Ile, pentylglycine, Val or Met;

Xaa<sub>15</sub> is Ala or Glu;

Xaa<sub>16</sub> is Ala or Glu;

Xaa<sub>17</sub> is Ala or Glu;

Xaa<sub>19</sub> is Ala or Val;

Xaa<sub>20</sub> is Ala or Arg;

Xaa<sub>21</sub> is Ala, Leu or Lys-NH<sup>0</sup>-R where R is Lys, Arg, C<sub>1</sub>-C<sub>10</sub> straight chain or branched alkanoyl or cycloalkylkanoyl;

Xaa<sub>22</sub> is Phe, Tyr or naphthylalanine;

Xaa<sub>23</sub> is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;

Xaa<sub>24</sub> is Ala, Glu or Asp;

Xaa<sub>25</sub> is Ala, Trp, Phe, Tyr or naphthylalanine;

Xaa<sub>26</sub> is Ala or Leu;

X<sub>1</sub> is Lys Asn, Asn Lys, Lys-NH<sup>0</sup>-R Asn, Asn Lys-NH<sup>1</sup>-R, Lys-NH<sup>0</sup>-R Ala, Ala Lys-NH<sup>0</sup>-R where R is Lys, Arg, C<sub>1</sub>-C<sub>10</sub> straight chain or branched alkanoyl or cycloalkylalkanoyl

USSN 09/554,533  
Atty Docket No. 238/086US

Z<sub>1</sub> is -OH,

-NH<sub>2</sub>,

Gly-Z<sub>2</sub>,

Gly Gly-Z<sub>2</sub>

Gly Gly Xaa<sub>31</sub>-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub>-Z<sub>2</sub>,

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub>-Z<sub>2</sub> or

Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub> Xaa<sub>38</sub>-Z<sub>2</sub>; wherein

Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> are independently

selected from the group consisting of Pro,

homoproline, 3Hyp, 4Hyp, thioproline,

N-alkylglycine, N-alkylpentylglycine and

N-alkylalanine; and

Z<sub>2</sub> is -OH or -NH<sub>2</sub>;

provided that no more than three of Xaa<sub>3</sub>, Xaa<sub>5</sub>, Xaa<sub>6</sub>, Xaa<sub>8</sub>, Xaa<sub>10</sub>, Xaa<sub>11</sub>, Xaa<sub>12</sub>, Xaa<sub>13</sub>, Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub>, Xaa<sub>17</sub>, Xaa<sub>19</sub>, Xaa<sub>20</sub>, Xaa<sub>21</sub>, Xaa<sub>24</sub>, Xaa<sub>25</sub>, and Xaa<sub>26</sub> are Ala; and pharmaceutically acceptable salts thereof.

36. (Withdrawn) A compound according to claim 35 wherein Xaa<sub>1</sub> is His, Tyr or 4-imidazopropionyl.

37. (Withdrawn) A compound according to claim 36 wherein Xaa<sub>1</sub> is His.

38. (Withdrawn) A compound according to claim 36 wherein Xaa<sub>1</sub> is 4-imidazopropionyl.

USSN 09/554,533  
Atty Docket No. 238/086US

39. (Withdrawn) A compound according to claim 35 wherein Xaa<sub>2</sub> is Gly.

40. (Withdrawn) A compound according to claim 35 wherein Xaa<sub>14</sub> is Leu, pentylglycine or Met.

41. (Withdrawn) A compound according to claim 35 wherein Xaa<sub>25</sub> is Trp or Phe.

42. (Withdrawn) A compound according to claim 35 wherein Xaa<sub>6</sub> is Phe or naphthylalanine; Xaa<sub>22</sub> is Phe or naphthylalanine; and Xaa<sub>23</sub> is Ile or Val.

43. (Withdrawn) A compound according to claim 35 wherein Z<sub>1</sub> is -NH<sub>2</sub>.

44. (Withdrawn) A compound according to claim 35 wherein Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> are independently selected from the group consisting of Pro, homoproline, thioproline and N-alkylalanine.

45. (Withdrawn) A compound according to claim 35 wherein Z<sub>2</sub> is -NH<sub>2</sub>.

46. (Withdrawn) A compound according to claim 35 wherein X<sub>1</sub> is Lys Asn, Lys-NH<sup>f</sup>-R Asn, or Lys-NH<sup>f</sup>-R Ala where R is Lys, Arg, C<sub>1</sub>-C<sub>10</sub> straight chain or branched alkanoyl.

47. (Withdrawn) A compound according to claim 35 wherein Xaa<sub>21</sub> is Lys-NH<sup>f</sup>-R where R is Lys, Arg, C<sub>1</sub>-C<sub>10</sub> straight chain or branched alkanoyl or cycloalkylkanoyl.

48. (Withdrawn) A compound according to claim 35 wherein said compound has an amino acid sequence selected from SEQ. ID. NOS. 67-74.

49. (Withdrawn) A composition comprising a compound of any of claims 35-47 in a pharmaceutically acceptable carrier.

USSN 09/554,533  
Atty Docket No. 238/086US

50. (Withdrawn) A composition comprising a compound of claim 48 in a pharmaceutically acceptable carrier.

51. (New) An exendin peptide compound of SEQ ID NO:29.

52. (New) A composition comprising a compound of claim 51 in a pharmaceutically acceptable carrier.

53. (New) A method for the treatment of diabetes mellitus comprising the administration of a therapeutically effective amount of a compound according to claim 51.

54. (New) The method of claim 53, further comprising the administration of a therapeutically effective amount of an insulin.